Taken together with data from prior studies, we can delineate three routes to AML development from MPN: abrupt expansion associated with biallelic TP53 loss; stepwise accumulation of additional driver mutations within already complex MPN clones; and emergence of a genetically independent de novo AML clone. This evidence concerns the gene TP53 and myeloproliferative disorder.